Treprostinil - United Therapeutics Corporation

Drug Profile

Treprostinil - United Therapeutics Corporation

Alternative Names: 15AU; 15AU81; ARD-1500; ARD-1550; BW 15AU; BW 15AU81; BW A15AU; LRX 15; MD 711; MD-0701; OreniCell; OreniLeft; Orenitram; Remodulin; Sustained-release treprostinil - United Therapeutics; TransCon treprostinil; Treprost; Treprostenol; Treprostinil diolamine; Treprostinol; Tresprostinol diethanolamine; Tyvaso; U 62840; Uniprost; UT 15; UT-15C; UT-15C SR

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Pfizer
  • Developer Ascendis Pharma; Ferrer; Lees Pharmaceutical Holdings; Mochida Pharmaceutical; United Therapeutics Corporation
  • Class Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase II Systemic scleroderma
  • Discontinued Cancer; Heart failure; Peripheral ischaemia

Most Recent Events

  • 09 Nov 2017 United therapeutics withdraws a phase III trial in Pulmonary arterial hypertension (Adjunctive therapy) in USA, prior to enrolment due to business reason (NCT02999906)
  • 24 Oct 2017 Mochida Pharmaceuticals plans a phase I trial for Pulmonary arterial hypertension in Japan (Inhalation) (Mochida Pharmaceuticals pipeline, October 2017)
  • 23 Oct 2017 United Therapeutics Corporation plans to launch TD 300/A, an inhalation device in for use in combination with treprostinil inhalation solution in mid 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top